Northpond Ventures, LLC

In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Northpond Ventures, LLC reported 3 stock positions worth $43.7 million. Its top holding was Kyverna Therapeutics (KYTX) at 36.5% of the portfolio, followed by Vigil Neuroscience (VIGL, 32.8%) and Candel Therapeutics (CADL, 30.7%). Compared with Q2 2024, it sold out of 1. The biggest sale was an exit from Telesis Bio (TBIO).

Most Recent 13F
Q3 2024
Location
Bethesda, MD
CIK
0001911245
Portfolio Value
$43.7M (Q3 2024)
SEC Filing
0001104659-24-118975 ↗ filed Nov 14, 2024

Holdings Value

0$50.0M$100.0M$150.0M Q1 2024: $102.6M Q1 2024 Q2 2024: $55.3M Q2 2024 Q3 2024: $43.7M $43.7M Q3 2024

Holdings 3 stocks · $43.7M
KYTX Kyverna Therapeutics Inc. 36.46% 3,255,426 $15.9M No change
VIGL Vigil Neuroscience Inc. 32.82% 4,214,498 $14.3M No change
CADL Candel Therapeutics Inc. 30.72% 1,935,215 $13.4M No change

Portfolio Sells Q2 2024 → Q3 2024
TBIO Telesis Bio Inc. Sold out 0.00% −3.61

Portfolio Buys Q2 2024 → Q3 2024
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q3 2024 3$43.7MKYTX, VIGL, CADL
Q2 2024 4$55.3MKYTX, VIGL, CADL, TBIO
Q1 2024 4$102.6MKYTX, VIGL, TELESIS BIO INC, CADL